74 related articles for article (PubMed ID: 35551087)
1. A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.
Bando Y; Hinata N; Omori T; Fujisawa M
BMJ Open; 2019 Dec; 9(12):e030522. PubMed ID: 31826889
[TBL] [Abstract][Full Text] [Related]
2. Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial.
Crabb S; Wickens R; Jane-Bibby S; Dunkley D; Lawrence M; Knight A; Jones R; Birtle A; Huddart R; Linch M; Martin J; Coleman A; Boukas K; Markham H; Griffiths G
BMC Cancer; 2023 Sep; 23(1):885. PubMed ID: 37726695
[TBL] [Abstract][Full Text] [Related]
3. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
[TBL] [Abstract][Full Text] [Related]
4. Localized Imaging of Programmed Death-Ligand 1 on Individual Tumor-Derived Extracellular Vesicles for Prediction of Immunotherapy Response.
Zhang J; Guan M; Lv M; Liu Y; Zhang H; Zhang Z; Zhang K
ACS Nano; 2023 Oct; 17(20):20120-20134. PubMed ID: 37819165
[TBL] [Abstract][Full Text] [Related]
5. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
Wang S; Huang HY; Wu D; Fang H; Ying J; Bai Y; Yu Y; Fang Y; Jiang N; Sun C; Yu A; Fan Q; Xing S; Ni Y; Zhang W; Wu C; Ji X; Wang H; Guo Y; Tang Q; Wang Y; Tang Y; Li N
BMJ Open; 2021 Jun; 11(6):e044543. PubMed ID: 34083331
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study).
Kong Y; Chen R; Xu M; Zhang J; Chen G; Hong Z; Zhang H; Dai X; Ma Y; Zhao X; Peng Y; Zhang C; Xing P; Zhang L
BMJ Open; 2024 Mar; 14(3):e075642. PubMed ID: 38458816
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.
Heilig CE; Horak P; Kreutzfeldt S; Teleanu V; Mock A; Renner M; Bhatti IA; Hutter B; Hüllein J; Fröhlich M; Uhrig S; Süße H; Heiligenthal L; Ochsenreither S; Illert AL; Vogel A; Desuki A; Heinemann V; Heidegger S; Bitzer M; Scheytt M; Brors B; Hübschmann D; Baretton G; Stenzinger A; Steindorf K; Benner A; Jäger D; Heining C; Glimm H; Fröhling S; Schlenk RF
ESMO Open; 2021 Dec; 6(6):100310. PubMed ID: 34808524
[TBL] [Abstract][Full Text] [Related]
8. Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology.
Kim AE; Nelson A; Stimpert K; Flyckt RL; Thirumavalavan N; Baker KC; Weinmann SC; Hoimes CJ
JCO Oncol Pract; 2022 Dec; 18(12):815-822. PubMed ID: 36174117
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC).
Cavalieri S; Vitolo V; Barcellini A; Ronchi S; Facoetti A; Campo C; Klersy C; Molinelli S; Agustoni F; Ferretti VV; Silvestri A; Platania M; Del Vecchio M; Durante M; Helm A; Fournier C; Braud F; Pedrazzoli P; Orlandi E; Licitra L
Future Oncol; 2023 Jan; 19(3):193-203. PubMed ID: 36974574
[TBL] [Abstract][Full Text] [Related]
10. Can radiation restore immunotherapy response in metastatic melanoma refractory to checkpoint inhibitors: An institutional experience in salvaging immunotherapy resistant disease.
Alhumaid M; Dinakaran D; Smylie M; Walker J; Joseph K
Radiother Oncol; 2023 Aug; 185():109712. PubMed ID: 37178931
[TBL] [Abstract][Full Text] [Related]
11. Consilium Smartphone App for Real-World Electronically Captured Patient-Reported Outcome Monitoring in Cancer Patients Undergoing anti-PD-L1-Directed Treatment.
Trojan A; Huber U; Brauchbar M; Petrausch U
Case Rep Oncol; 2020; 13(2):491-496. PubMed ID: 32518544
[TBL] [Abstract][Full Text] [Related]
12. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.
Wong MK; Kaufman HL; Daniels GA; McDermott DF; Aung S; Lowder JN; Morse MA
J Immunother Cancer; 2014; 2():20. PubMed ID: 25031835
[TBL] [Abstract][Full Text] [Related]
13. The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients.
Chmielewska I; Grenda A; Krawczyk P; Frąk M; Kuźnar Kamińska B; Mitura W; Milanowski J
Cancer Immunol Immunother; 2023 Dec; 72(12):4169-4177. PubMed ID: 37816808
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Vesicles in Cancer Drug Resistance: Implications on Melanoma Therapy.
Musi A; Bongiovanni L
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831417
[TBL] [Abstract][Full Text] [Related]
15. Extracellular Vesicles-Based Cell-Cell Communication in Melanoma: New Perspectives in Diagnostics and Therapy.
Kluszczynska K; Czyz M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674479
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity.
Lucien F; Kim Y; Qian J; Orme JJ; Zhang H; Arafa A; Abraha F; Thapa I; Tryggestad EJ; Harmsen WS; Kosti J; Ali H; Lowe VJ; Johnson GB; Kwon ED; Dong H; Park SS
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):725-737. PubMed ID: 35671867
[TBL] [Abstract][Full Text] [Related]
17. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy.
Davidson TM; Foster N; Lucien F; Markovic S; Dong H; Winters JL; Park SS; Orme JJ
BMJ Open; 2022 May; 12(5):e050112. PubMed ID: 35551087
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles.
Orme JJ; Enninga EAL; Lucien-Matteoni F; Dale H; Burgstaler E; Harrington SM; Ball MK; Mansfield AS; Park SS; Block MS; Markovic SN; Yan Y; Dong H; Dronca RS; Winters JL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817395
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
